Biosimilar drugs breaking high-cost barrier to cancer immunotherapy
Biosimilar nivolumab is boosting access to cancer immunotherapy in India, cutting per-cycle costs from Rs 1 lakh+ to ~Rs 30,000; more price caps planned.
The Times of India asks for a subscription to read the full story. If you have one, sign in on their site.
0 comments